NCT00419536
Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone treatment 1 terminated NCT00411853
Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients No drug interventions treatment 2 unknown_status NCT02867345
PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer Not Available Not Available withdrawn NCT02208583
Molecular Phenotype Changes and Personalized Treatment for CRPC Not Available Not Available unknown_status NCT01260688
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel treatment 2 completed NCT01083615
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) treatment 3 terminated NCT00928252
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer diagnostic 1 / 2 completed NCT00133900
Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy No drug interventions Not Available Not Available unknown_status NCT02691975
A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients treatment 1 / 2 unknown_status NCT00571675
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) treatment 2 completed NCT01215799
Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer treatment 2 completed NCT00667199
BAY88-8223, Does Response Study in HRPC Patients treatment 2 completed NCT00286806
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer treatment 1 / 2 completed NCT00510718
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer treatment 1 completed NCT00583024
Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer No drug interventions treatment 2 completed NCT01487863
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer basic_science 2 completed NCT00629525
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer treatment 2 completed NCT00313482
PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC treatment 2 terminated NCT00156884
A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer treatment 2 completed NCT00699751
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases treatment 3 completed NCT00407251
Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy treatment 2 completed NCT00987753
Study Evaluating the Safety and Tolerability of L-377202 treatment 1 / 2 completed NCT00069745
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen treatment 3 completed NCT01590498
Radiotherapy vs Observation for CRPC No drug interventions Not Available Not Available unknown_status NCT01518283
Study of Weekly Cabazitaxel for Advanced Prostate Cancer treatment 2 completed NCT00795171
Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer basic_science 2 unknown_status NCT00448734
A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer treatment 1 / 2 unknown_status NCT01741116
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer treatment 2 completed NCT00493766
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone treatment 1 terminated NCT02955082
The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment treatment 2 recruiting NCT01194960
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC) treatment 2 terminated NCT00286091
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer prevention 3 completed NCT00477529
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer treatment 1 / 2 completed NCT00525408
A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer treatment 2 terminated NCT00906243
RNActive®-Derived Therapeutic Vaccine No drug interventions treatment 1 / 2 terminated NCT00891345
Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy treatment 1 completed NCT01631552
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer treatment 1 / 2 completed NCT02288936
Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer treatment 2 completed NCT00082134
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel No drug interventions treatment 2 completed NCT03658434
Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer No drug interventions treatment Not Available unknown_status NCT00201357
An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer treatment 2 completed NCT00151073
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate treatment 2 completed NCT01133704
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer treatment 3 completed NCT01422850
Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy treatment 1 completed NCT00337077
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy treatment 2 completed NCT00675545
A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients treatment 2 completed NCT01020305
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer treatment 1 / 2 terminated NCT01450683
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy treatment 2 terminated NCT05997615
Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Metastatic Castration Resistant Prostate Cancer (mCRPC) No drug interventions treatment 1 / 2 recruiting NCT00570700
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer treatment 2 completed NCT00048659
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy No drug interventions treatment 2 terminated NCT03016741
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer supportive_care 4 unknown_status NCT00636740
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients treatment 2 completed NCT03076203
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) treatment 1 completed